ARS Pharmaceuticals, Inc. Upgraded to Buy: Here's Why - ARS Pharmaceuticals ( NASDAQ:SPRY )

2 weeks ago

ARS Pharmaceuticals, Inc. SPRY could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 ( Buy ) . This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

Ticker	Sentiment	Impact
SPRY	Somewhat Bullish	34 %